(February 3, 2021 / JNS) The Israeli Health Ministry on Wednesday announced that beginning on Thursday, COVID-19 vaccines would be available to all Israelis over the age of 16.
As of Wednesday morning, 3,237,163 people in Israel had received the first dose of Pfizer’s BioNTech vaccine and 1,855,785 had received two doses, according to Health Ministry data. However, despite the country’s aggressive vaccination campaign, which has been conducted during its third full lockdown since the crisis began in March, morbidity has dropped troublingly slowly, with 9.3 percent of the coronavirus tests conducted on Tuesday returning positive results.
According to Israeli Health Minister Yuli Edelstein, the main culprit is the so-called U.K. variant of the COVID-19 virus, which Israeli Prime Minister Benjamin Netanyahu on Tuesday said constituted 80 percent of all new confirmed infections, up from 70 percent just days ago.
At a joint press conference with Edelstein on Tuesday, Netanyahu said that Israel was in a race between the vaccination campaign and the virus variant, and said that prioritizing for inoculation those over the age of 50 will be key to successfully exiting the lockdown.
“Ninety-seven percent of those who have died are in the 50-and-over age group. Almost 100 percent of the deceased are there,” he said. Ninety-three percent of serious cases of infection fall in this group, as well, he added.
He thus proposed as a “national goal” vaccinating at least 90 percent of those in this age group within a two-week span, noting that this was achievable, as 77 percent of them have already been vaccinated. He vowed to present the proposal, along with a lockdown exit plan, to the Cabinet.
Jewish News Syndicate
With geographic, political and social divides growing wider, high-quality reporting and informed analysis are more important than ever to keep people connected.
Our ability to cover the most important issues in Israel and throughout the Jewish world—without the standard media bias—depends on the support of committed readers.
If you appreciate the value of our news service and recognize how JNS stands out among the competition, please click on the link and make a one-time or monthly contribution.
We appreciate your support.